Novartis has given its support to the first online community specifically for patients affected by a rare form of pancreatic cancer.
The Pancreatic Neuroendocrine Tumor (PNET) Support Community is a peer-to-peer support community for patients and carers from around the world to share information and support.
Created by New Jersey-based agency Inspire, the community’s patient group partners include the Carcinoid Cancer Foundation and the Pancreatic Cancer Action Network.
Novartis, whose interest in the area centres around Afinitor (everolimus), will be the site’s corporate sponsor.
Inspire’s CEO Brian Loew said: “We have seen repeatedly how online patient networks can empower people affected by rare diseases.
“We’re grateful for the support of our nonprofit partners, and to Novartis, all of whom understood that PNET patients needed this kind of resource in which they can exchange information with others facing the same serious health challenges.”
Group members discuss such topics as practical tips for the newly diagnosed, chemotherapy and targeted therapies, and surgical options, Inspire said.
